GlassScriptPhysician profile
Myrrh E Hector
NPI 1912691544
$1,008.64
in general payments reported to CMS, 2019-2025
12 companies · $542 in 2025
The $542 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $108 · 2024: $358 · 2025: $542.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,009.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,008.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $218.16 | 2024-2025 | Breztri, Airsupra, Farxiga |
| Amgen INC. | $156.43 | 2023-2025 | Repatha, Otezla, Otezla |
| Novo Nordisk INC | $128.41 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Exact Sciences Corporation | $119.80 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $93.59 | 2024-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $81.14 | 2023-2025 | |
| Glaxosmithkline, LLC. | $64.40 | 2023-2025 | Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $54.71 | 2024-2025 | Xifaxan, Trulance |
| Sanofi-Aventis U.S. LLC | $38.20 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $18.78 | 2025 | Rexulti |
| Abbvie INC. | $18.72 | 2024 | |
| Medtronic, INC. | $16.30 | 2024 | Interstim |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Myrrh Hector listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.